Wet age-related macular degeneration, or AMD, is a chronic eye condition that damages the macula, a small area near the center of your retina. This part of your eye helps you see objects that are ...

Regenxbio released positive new data from a Phase 2 trial investigating its experimental one-time gene therapy for bilateral ...

In this video, we will cover treatment types, costs, insurance factors, and financial assistance for wet AMD. Types of wet AMD treatments. The main treatment involves eye injections of anti-VEGF ...

Dr Arshad Khanani previews the 2024 American Academy of Ophthalmology Annual Meeting, particularly the retina subspecialty day focusing on wet age-related macular degeneration (AMD), with highlights ...

Clearside is now looking at a Phase III trial as it plans to meet with the FDA early next year to discuss the new Phase IIb ...

For years, anti-VEGF injections have helped to preserve sight in people with wet AMD by controlling the growth of leaky abnormal blood vessels that could otherwise damage the retina in this form of ...

Researchers conducted a large observational study to provide “a snapshot of US ophthalmic care” that they hoped would provide information linking certain patient characteristics with eye care ...

REGENXBIO Presents Positive Data from the Phase II Study of Subretinal ABBV-RGX-314 in Patients with Bilateral Wet AMD at AAO ...

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today positive topline one-year results from ...

Opthea Limited (ASX/NASDAQ: OPT, “Opthea”, the “Company”), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, including ...

“The exceptional pace of SOL-1 recruitment reflects the strong continued interest from investigators and patients in AXPAXLI’s potential to significantly alter the wet AMD treatment paradig ...